HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: Relevance for clinical classification: retrospective study of 169 patients.

AbstractOBJECTIVE:
The current study was performed in order to determine the prevalence of different myositis-specific and myositis-associated antibodies, as well as their association with clinical characteristics, disease course and response to therapy in 169 Hungarian patients with idiopathic inflammatory myopathy.
METHODS:
Sera of 130 primary and 39 overlap myositis including systemic sclerosis (13), rheumatoid arthritis (12), systemic lupus erythematosus (5) and Sjögren's syndrome (9) cases were analyzed. Antinuclear antibody, scleroderma-associated antibodies (anti-centromere, anti-topoisomerase I), anti-Jo-1, anti-PL-7, anti-PL-12, anti-Mi-2, anti-SRP and anti-PM-Scl, anti-Ku, anti-SS-A, anti-SS-B, anti-U1snRNP were tested. Autoantibody results were compared with clinical characteristics, disease course of overlap versus primary myositis patients, as well as with response to therapy.
RESULTS:
Associated connective tissue disease occurred in 23.1% of the patients. Myositis-associated antibodies were found in 8.5% of primary myositis patients, indicating that 11 additional primary myositis patients (23% vs. 29.6%) can be classified as overlap in all cohort according to the newly proposed diagnostic criteria. Polymyositis was found to be the most common myositis form in overlap myositis (87.2%), while scleroderma was the most common disease associated (33.3%). ANA was positive in 25.4% of primary and in 61.5% of overlap myositis cases. Altogether 39.6% of myositis patients (n=67) had autoantibodies, most commonly anti Jo-1 (18.3%) correlating with a polycyclic disease course.
CONCLUSION:
Inclusion of myositis-specific and associated antibodies into the newly proposed diagnostic criteria for inflammatory myopathies is of great importance in order to determine subclasses and to introduce adequate therapy in time.
AuthorsAndrea Váncsa, Lajos Gergely, Andrea Ponyi, Gabriella Lakos, Júlia Németh, Péter Szodoray, Katalin Dankó
JournalJoint bone spine (Joint Bone Spine) Vol. 77 Issue 2 Pg. 125-30 (Mar 2010) ISSN: 1778-7254 [Electronic] France
PMID20188618 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2010 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.
Chemical References
  • Autoantibodies
  • Immunosuppressive Agents
Topics
  • Adolescent
  • Adult
  • Aged
  • Autoantibodies (blood, immunology)
  • Cross-Sectional Studies
  • Dermatomyositis (classification, drug therapy, epidemiology, immunology)
  • Female
  • Follow-Up Studies
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Male
  • Middle Aged
  • Polymyositis (classification, drug therapy, epidemiology, immunology)
  • Retrospective Studies
  • Seroepidemiologic Studies
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: